Compare New York Times Co (NYT) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Viatris Inc — how do they compare? New York Times Co trades at $66.6 (market cap $10.96B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| NYT | VTRS | |
|---|---|---|
Market Cap | $10.96B | $19.09B |
Sector | Media | Health |
52-Week High | $85.86 | $17.86 |
52-Week Low | $54.66 | $9.49 |
Enterprise Value | $10.36B | $31.21B |
Dividend Yield | 1.35% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $67.96, up 1.01% today, with a neutral technical signal. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 highlight strong operational performance, supported by rising revenue and net income margins. The stock's valuation metrics include a P/E of 28.32 and P/S of 3.75, while positive cash flow trends and a dividend payment reflect financial stability.
Outlook remains cautiously optimistic with a consensus price target of $76.00, offering potential upside. Key risks include ongoing legal challenges with OpenAI over copyright issues and competitive pressures in digital media. Institutional interest is evident, but regulatory and market sentiment uncertainties warrant monitoring for sustained growth.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
